ATE307603T1 - Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1 - Google Patents
Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1Info
- Publication number
- ATE307603T1 ATE307603T1 AT99967463T AT99967463T ATE307603T1 AT E307603 T1 ATE307603 T1 AT E307603T1 AT 99967463 T AT99967463 T AT 99967463T AT 99967463 T AT99967463 T AT 99967463T AT E307603 T1 ATE307603 T1 AT E307603T1
- Authority
- AT
- Austria
- Prior art keywords
- glucagon
- peptide
- liquid compositions
- stable liquid
- storage stable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11349998P | 1998-12-22 | 1998-12-22 | |
PCT/US1999/030395 WO2000037098A1 (en) | 1998-12-22 | 1999-12-21 | Shelf-stable formulation of glucagon-like peptide-1 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE307603T1 true ATE307603T1 (de) | 2005-11-15 |
Family
ID=22349808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99967463T ATE307603T1 (de) | 1998-12-22 | 1999-12-21 | Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1140148B1 (de) |
JP (1) | JP4689833B2 (de) |
AT (1) | ATE307603T1 (de) |
AU (1) | AU2373400A (de) |
CA (1) | CA2358107C (de) |
DE (1) | DE69928006T2 (de) |
DK (1) | DK1140148T3 (de) |
ES (1) | ES2249933T3 (de) |
WO (1) | WO2000037098A1 (de) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6663602B2 (en) | 2000-06-16 | 2003-12-16 | Novo Nordisk A/S | Injection device |
US7090869B2 (en) | 2000-12-01 | 2006-08-15 | Takeda Pharmaceutical Company Limited | Method for producing preparation containing bioactive substance |
JP5562510B2 (ja) * | 2001-06-28 | 2014-07-30 | ノヴォ ノルディスク アー/エス | 修飾glp−1の安定な処方剤 |
JP2005508895A (ja) | 2001-08-28 | 2005-04-07 | イーライ・リリー・アンド・カンパニー | Glp−1および基礎インスリンの予備混合物 |
US7179788B2 (en) | 2001-10-19 | 2007-02-20 | Eli Lilly And Company | Biphasic mixtures of GLP-1 and insulin |
CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
BRPI0408978B8 (pt) | 2003-04-08 | 2021-07-27 | Novo Nordisk As | processos para regenerar uma fase estacionária cromatográfica |
WO2004089985A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Stable pharmaceutical compositions |
ATE541582T1 (de) | 2003-06-03 | 2012-02-15 | Novo Nordisk As | Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen |
PL1633390T3 (pl) * | 2003-06-03 | 2012-06-29 | Novo Nordisk As | Stabilizowane kompozycje farmaceutyczne peptydu glp-1 |
EP1633391B1 (de) * | 2003-06-03 | 2011-10-19 | Novo Nordisk A/S | Stabilisierte pharmazeutische peptid zusammensetzungen |
ES2375056T3 (es) * | 2003-06-03 | 2012-02-24 | Novo Nordisk A/S | Composiciones pept�?dicas farmacéuticas estabilizadas. |
KR101243648B1 (ko) | 2003-11-20 | 2013-03-14 | 노보 노르디스크 에이/에스 | 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제 |
EP1789434B1 (de) | 2004-08-31 | 2013-11-20 | Novo Nordisk A/S | Verwendung von tris(hydroxymethyl)-aminomethan zur stabilisierung von peptiden, polypeptiden und proteinen |
WO2006045526A1 (en) | 2004-10-21 | 2006-05-04 | Novo Nordisk A/S | Dial-down mechanism for wind-up pen |
CA2586771A1 (en) * | 2004-11-12 | 2006-05-18 | Novo Nordisk A/S | Stable formulations of insulinotropic peptides |
JP5248113B2 (ja) * | 2004-11-12 | 2013-07-31 | ノヴォ ノルディスク アー/エス | ペプチドの安定な処方 |
MX2010005245A (es) | 2007-11-16 | 2010-06-01 | Novo Nordisk As | Composiciones farmaceuticas que comprenden peptidos glp-1 o exendin-4 y un peptido de insulina basal. |
US20110269680A1 (en) * | 2008-12-29 | 2011-11-03 | Panacea Biotec Limited | Glp-1 analogs and uses thereof |
EP2435061A4 (de) | 2009-05-28 | 2013-03-27 | Amylin Pharmaceuticals Inc | Schlaffördernde glp-1-rezeptor-agonistenverbindungen |
EP2496249B1 (de) | 2009-11-03 | 2016-03-09 | Amylin Pharmaceuticals, LLC | Glp-1-rezeptor-agonisten zur verwendung in der behandlung von obstruktiver schlafapnoe |
EP2654767A4 (de) | 2010-12-22 | 2014-05-21 | Amylin Pharmaceuticals Inc | Glp-1-rezeptoragonisten zur inselzelltransplantation |
MX2014007375A (es) | 2011-12-29 | 2014-08-22 | Novo Nordisk As | Jeringa autoinyectora de cuerda basada en resorte de torsion con mecanismo dosificador giratorio de aumento/disminucion. |
US20150359864A1 (en) * | 2012-03-09 | 2015-12-17 | Oncotherapy Science, Inc. | Pharmaceutical composition containing peptides |
EP2873422A4 (de) | 2012-07-10 | 2015-12-30 | Takeda Pharmaceutical | Pharmazeutische zubereitung zur injektion |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
JP2016503771A (ja) | 2012-12-21 | 2016-02-08 | サノフイ | エキセンジン−4誘導体 |
CN103405753B (zh) * | 2013-08-13 | 2016-05-11 | 上海仁会生物制药股份有限公司 | 稳定的促胰岛素分泌肽水针药物组合物 |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
EP3080150B1 (de) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
EP3080149A1 (de) | 2013-12-13 | 2016-10-19 | Sanofi | Duale glp-1-/glucagon-rezeptoragonisten |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
JP6948330B2 (ja) | 2015-12-23 | 2021-10-13 | アムジエン・インコーポレーテツド | 胃抑制ペプチド受容体(gipr)に対する結合タンパク質をglp−1アゴニストと組み合わせて使用する、代謝障害の治療方法または寛解方法 |
JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
PE20200013A1 (es) | 2017-06-20 | 2020-01-06 | Amgen Inc | Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1 |
CN111050750A (zh) | 2017-08-24 | 2020-04-21 | 诺沃挪第克公司 | Glp-1组合物及其用途 |
WO2020208541A1 (en) * | 2019-04-08 | 2020-10-15 | Enzene Biosciences Limited | Composition comprising glp-1 analogue |
WO2021053578A1 (en) * | 2019-09-19 | 2021-03-25 | Dr. Reddy’S Laboratories Limited | Improved purification processes for liraglutide |
WO2021142733A1 (en) * | 2020-01-16 | 2021-07-22 | Shanghai Benemae Pharmaceutical Corporation | Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs |
MX2022009523A (es) | 2020-02-18 | 2022-09-09 | Novo Nordisk As | Formulaciones farmaceuticas. |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0587255A1 (de) * | 1986-05-05 | 1994-03-16 | The General Hospital Corporation | Insulinotropische Hormone |
US5118666A (en) * | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
DK36492D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Praeparat |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
JPH10511365A (ja) * | 1994-12-23 | 1998-11-04 | ノボ ノルディスク アクティーゼルスカブ | 遅延性glp−1組成物 |
-
1999
- 1999-12-21 CA CA2358107A patent/CA2358107C/en not_active Expired - Fee Related
- 1999-12-21 DE DE69928006T patent/DE69928006T2/de not_active Expired - Lifetime
- 1999-12-21 AT AT99967463T patent/ATE307603T1/de active
- 1999-12-21 AU AU23734/00A patent/AU2373400A/en not_active Abandoned
- 1999-12-21 JP JP2000589208A patent/JP4689833B2/ja not_active Expired - Fee Related
- 1999-12-21 DK DK99967463T patent/DK1140148T3/da active
- 1999-12-21 EP EP99967463A patent/EP1140148B1/de not_active Expired - Lifetime
- 1999-12-21 WO PCT/US1999/030395 patent/WO2000037098A1/en active IP Right Grant
- 1999-12-21 ES ES99967463T patent/ES2249933T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO2000037098A1 (en) | 2000-06-29 |
EP1140148A1 (de) | 2001-10-10 |
ES2249933T3 (es) | 2006-04-01 |
DE69928006D1 (de) | 2005-12-01 |
DK1140148T3 (da) | 2006-01-30 |
JP2002532557A (ja) | 2002-10-02 |
AU2373400A (en) | 2000-07-12 |
CA2358107A1 (en) | 2000-06-29 |
JP4689833B2 (ja) | 2011-05-25 |
CA2358107C (en) | 2011-08-23 |
EP1140148B1 (de) | 2005-10-26 |
DE69928006T2 (de) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE307603T1 (de) | Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1 | |
HK1024865A1 (en) | Pharmaceutical compositions comprising a mixture of autocross-linked hyaluronic acid and nonautocross-linked hyaluronic acid and their use for the treatment of arthropathies | |
EA200300026A1 (ru) | Аналоги глюкагоноподобного пептида-1 | |
DK0949907T3 (da) | Fremgangsmåder og præparater til forbedret biotilgængelighed og biologisk aktive midler til slimhindeadministration | |
NO971889D0 (no) | Forbindelser og sammensetninger for levering av aktive midler | |
RU97118224A (ru) | Соединения и композиции для доставки активных агентов | |
DK0566709T5 (da) | Præparat indeholdende et tramadolmateriale og acetaminophen og anvendelse deraf | |
BG103800A (en) | Method and composition for the treatment of apnoea | |
MXPA02011339A (es) | Tratamiento del sindrome coronario agudo con glp-1. | |
AU7226301A (en) | Pyridoxine and pyridoxal analogues: cardiovascular therapeutics | |
NO940436L (no) | Forlenget avgivelse av peptider | |
PL319608A1 (en) | Compositions for treating irds and ards, containing at least one glucocorticosteroid in a mixture with a pulmonic surfactant | |
CA2138161A1 (en) | Glucagon-like peptide and insulinotropin derivatives | |
MY125556A (en) | Aqueous formulations of peptide | |
RU92004549A (ru) | Высокодозированные формы коллагеназы для наружного применения | |
DE69333378D1 (de) | Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren | |
ATE214090T1 (de) | Pentafluorbutan enthaltende zusammensetzungen und deren anwendung | |
EA199900876A1 (ru) | Фармацевтические композиции против кашля | |
PL340561A1 (en) | Application of a combination of a converting enzyme inhibitor and a diuretic in treating microcirculatory disorders | |
WO2001034172A3 (en) | Methods and compositions for treating reward deficiency syndrome | |
DK0901790T3 (da) | Anvendelse af moxonidin til behandling af neuropatisk smerte | |
MX9504023A (es) | Composicion farmaceutica y transdermicamente activa que contiene acido 5-aminolaevulinico y procedimiento para su preparacion. | |
DE69213935T2 (de) | Neue heterocyclische carbonsäuren | |
BG104062A (en) | Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor | |
BG103543A (en) | The use of pramipexol in the treatment of the uneasy legs syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1140148 Country of ref document: EP |